ARTICLE | Company News
Pfizer, MD Anderson partner for cancer combo clinical trials
September 29, 2017 9:35 PM UTC
University of Texas MD Anderson Cancer Center (Houston, Texas) partnered with Pfizer Inc. (NYSE:PFE) to identify patients who respond to immunotherapy and evaluate combinations of Pfizer’s immuno-oncology candidates in a series of clinical trials.
MD Anderson will conduct at least five Phase Ib trials in patients with solid tumors and hematologic malignancies. MD Anderson expects the majority of the trials to begin in late 2017...